VF
TVTX icon

Virtu Financial’s Travere Therapeutics TVTX Stock Holding History

Virtu Financial’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,500
Closed -$301K – 2069
2024
Q3 		$301K Buy
+21,500
New +$224K 0.02% 628
2024
Q1 		– Sell
-19,498
Closed -$175K – 2116
2023
Q4 		$175K Buy
+19,498
New +$142K 0.01% 881

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Virtu Financial's TVTX Position: Q4 2024 in Review

Virtu Financial sold out of Travere Therapeutics (TVTX) in Q4 2024, closing a stake of 21,500 shares — an estimated $301K sold.

Virtu Financial first reported a position in TVTX in Q4 2023 and held it in 2 quarters. The position peaked at $301K in Q3 2024. 197 funds tracked by Wall St. Rank hold TVTX as of Q4 2024.

  • Virtu Financial reported no remaining Travere Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Virtu Financial sold 21,500 Travere Therapeutics shares in Q4 2024, an estimated $301K.
  • Virtu Financial first reported a position in Travere Therapeutics in Q4 2023 and held it in 2 quarters.
  • Virtu Financial's Travere Therapeutics position peaked at $301K in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2024.

Based on Virtu Financial's 13F filing for Q4 2024, filed 11 Feb 2025.